[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1995023563A1 - Protheses endovasculaires hepatiques - Google Patents

Protheses endovasculaires hepatiques Download PDF

Info

Publication number
WO1995023563A1
WO1995023563A1 PCT/CA1995/000124 CA9500124W WO9523563A1 WO 1995023563 A1 WO1995023563 A1 WO 1995023563A1 CA 9500124 W CA9500124 W CA 9500124W WO 9523563 A1 WO9523563 A1 WO 9523563A1
Authority
WO
WIPO (PCT)
Prior art keywords
rigid
prosthesis
flexible
stent
flexible member
Prior art date
Application number
PCT/CA1995/000124
Other languages
English (en)
Other versions
WO1995023563B1 (fr
Inventor
Gilles Pomier-Layrargues
Original Assignee
Universite De Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite De Montreal filed Critical Universite De Montreal
Priority to AU17521/95A priority Critical patent/AU1752195A/en
Publication of WO1995023563A1 publication Critical patent/WO1995023563A1/fr
Publication of WO1995023563B1 publication Critical patent/WO1995023563B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958—Inflatable balloons for placing stents or stent-grafts

Definitions

  • the present invention relates to endovascular hepatic prostheses and, more particularly, to improved intrahepatic portal- systemic shunts.
  • Hepatic insufficiency is a known reversible state which leads to death in a relatively short time. In such case, a hepatic transplant is considered as the best treatment. Moreover, patients often have to wait for a substantially long period of time, e.g. more than one year, before obtaining a graft. During this period, numerous complications of the hepatic insufficiency may appear in an unpredictable manner.
  • Expandable intraluminal stents were initially developed for preventing reocclusion of delayed restenosis after percutaneous transluminal balloon angioplasty of occluded arteries. Intraluminal metal stents were then used in the biliary system in an animal model. Expandable biliary stents are introduced through a small transhepatic tract and, once in place, are expanded to a larger diameter for maintaining antegrade bile flow for a long period of time.
  • Intrahepatic portal-systemic shunt is characterized by the creation of a fistulous tract between branches of the hepatic and intrahepatic portal veins through the intervening hepatic parenchyma. In their crudest form, intrahepatic portal-systemic shunts are simply parenchymal tracts connecting the two vessels. Transjugular intrahepatic portal-systemic stent-shunts are more specific in using expandable metal stents which have been placed between branches of the portal and systemic venous systems. The acronym TIPS is used for the transjugular intrahepatic portal-systemic shunts.
  • the procedure is almost always formed through the jugular vein thereby explaining the use of the term "transjugular" .
  • the procedure can also be performed through the femoral veins.
  • the exact anatomic sight of the skin puncture is irrelevant.
  • the term TIPS will be herein used to cover all intrahepatic portal- systemic shunt procedures.
  • balloon expandable stents which are expanded by inflation of an angioplasty balloon
  • self-expandable stents which have an intrinsic expanding force
  • a well-known balloon expandable stent is the Palmaz stent which is an expandable metal stent for intraarterial use that was employed to keep the hepatic parenchymal tract patent.
  • the Palmaz stent is a seamless tube of electropolished medical grade stainless steel, with staggered parallel slots defined through its wall. In the collapsed state, the Palmaz stent has a diameter of 3.1 mm and the length of 30 mm. For positioning, the Palmaz stent has to be crimped on a high pressure, Gruentzig-type balloon. By expanding this angioplasty balloon, the stent is dilated to a predetermined diameter (i.e. 8 to 12 mm). Full expansion reduces the length of the stent to 25 mm.
  • the Palmaz stent With the expansion of the Palmaz stent, the slots defined in the wall thereof assume a diamond shape and the open area within the metal mesh increases to a maximum of 88%.
  • the Palmaz stent is rigid in the longitudinal axis thereof and has a very high resistance to circumferential radial pressure.
  • the stent is fairly radiopaque.
  • the balloon mounted Palmaz stent is inserted through a 10 F, 40 cm long introducer sheath. A metallic introducing cannula is required to pass the Palmaz stent through the sheath valve.
  • the 10 F sheath is withdrawn proximal to the balloon and a test injection is performed to check the position of the stent which can be corrected, if required.
  • the Palmaz stent is then deployed by injecting a mixture of saline and dye into the angioplasty balloon. As the ends of the Palmaz stent expand first, movement of the stent after partial expansion thereof is dangerous and has to be avoided. After complete deflation of the balloon, the sheath can again be advanced and the angioplasty balloon catheter can be withdrawn. Since the Palmaz stent is short, multiple stents may have to be placed in an overlapping end-to-end fashion. Gradually, the shunt while remaining patent becomes covered by a layer of endothelial cells.
  • the second type of expandable metal stent that is the self-expandable stent having an intrinsic expanding force is made of biomedical superalloy monofilament wire (cold-formed cobalt- chromium-nickel-molybdenum-iron alloy) braided in a tubular mesh configuration, the stent being flexible, compliant and self-expanding.
  • the wire mesh consists of twenty-four braided wires with unfixed crossing points.
  • the compressed stent premounted on a 7 F catheter has a length of 42 or 68 mm and a diameter of 2 mm. After release, the stent expands to a diameter of 8 or 10 mm and its length reduces by approximately 32%.
  • the WallstentTM which has longitudinal and radial elasticity and which, after deployment and fixation of the stent at the proximal and distal ends thereof, is moderately resistant to circumferential stress. It is noted that the stent has low radiopacity.
  • the WallstentTM is premounted on a 7 F catheter and then covered by a thin invaginated rolling polyurethane membrane which serves to keep the stent compressed during the insertion thereof. Therefore, the WallstentTM can be inserted through a regular 7 F catheter introducer sheath. To deploy the stent, the two sheaths of the invaginated rolling membrane are separated hydraulically and the membrane is retracted.
  • the WallstentTM will pass through a 7 F catheter introducer sheath and the stent will be inserted in a single step procedure.
  • the WallstentTM catheter has been prepared by filling the hydraulic membrane with contrast material.
  • the 7 F sheath is withdrawn to avoid compressing the hydraulic membrane.
  • the WallstentTM catheter is properly positioned across the intra-parenchymal tract by way of the radiopaque markers provided thereon (one at both ends of the stent and a middle marker which indicates the shortening) . Under a predetermined pressure, the hydraulic membrane is withdrawn thereby allowing the deployment of the WallstentTM. Corrections to the stent position are possible as long as the membrane holds the stent on the catheter. It is important to maintain the proper pressure (e.g.
  • an intrahepatic portal-systemic stent is one of the most complex procedures in interventional medicine, and two stents are now widely used, that is the above Palmaz balloon expandable stent and the WallstentTM, the former being a relatively rigid stent that is usually expanded to 12 mm in diameter but can be expanded to 16 mm, while the former is a self-expanding stent that is much more flexible than the Palmaz stent.
  • the WallstentTM retains its circular shape even when flexed at relatively sharp angles; furthermore, because of its flexibility, the WallstentTM is easier to insert.
  • the surgical procedure includes the following steps with respect to a WallstentTM which is passed through the right jugular vein.
  • An angiography catheter is guided into a large hepatic vein and then replaced by a Colapinto transjugular needle which is directed towards the hepatic parenchyma towards the hilum of the liver.
  • the needle is slowly withdrawn under suction and when blood is aspirated, the vessel is identified by contrast injection.
  • the needle is replaced by a balloon catheter within the Colapinto catheter after the portal vein is entered.
  • the balloon catheter is positioned across the parenchymal tract and inflated with contrast medium to a diameter of 10 mm.
  • the balloon and Colapinto catheters are then removed and, for instance, a 7 F delivery catheter is passed, a WallstentTM covered by a retractable plastic sheath or membrane being mounted on this delivery catheter.
  • a 7 F delivery catheter is passed, a WallstentTM covered by a retractable plastic sheath or membrane being mounted on this delivery catheter.
  • an appropriate stent is deployed by pulling back the membrane which detaches the stent from the catheter in view of the intrinsic expanding force of the stent.
  • the stent thus deploys to extend completely through the parenchymal tract, extending about 5 mm into both the hepatic and portal veins. It is noted that if the stent is too short, a second overlapping stent can be distended within the original one thereby increasing the length of the endoprostheses (as for the Palmaz stent) .
  • Palmaz stent is more difficult to insert because of its rigidity and it is thus required to insert the Palmaz stent into larger, more centrally located veins.
  • its larger diameter alloys for a single shunt to decompress the portal system completely whereas complete decompression with the WallstentTM may require the deployment of two distinct hepatic portal shunts, e.g. having 8 and 10 mm diameters.
  • a new stent can be positioned within the original one and expanded to restore the lumen virtually to its original diameter.
  • intrahepatic portal-systemic shunts or stents are especially well suited to patients awaiting liver transplantation and it is a much less invasive procedure than surgical portal- systemic anastomosis which cannot be tolerated in most such patients.
  • the existence of an intrahepatic stent that is removed during hepatectomy does not increase the technical difficulty of performing a liver transplant, as surgical portal-systemic shunts often do.
  • intrahepatic portal-systemic shunts appear, by reducing portal hypertension and mobilizing ascites, to improve nutrition and thus to improve hepatic function enough to eliminate entirely the need for a new liver in some patients.
  • Intrahepatic portal-systemic shunts or stents can produce complications, principally such as hepatic encephalopathy (i.e. HE) and stent stenosis which leads in some cases to occlusion of the stent.
  • hepatic encephalopathy i.e. HE
  • stent stenosis which leads in some cases to occlusion of the stent.
  • a positive aspect of intrahepatic portal-systemic shunts or stents lies in its high rate of successful implantation and its low incidence of complications.
  • Studies of the body's response to these foreign bodies or prostheses inserted into the center of the liver show that these stainless steel stents are accepted by the liver and are promptly covered by endothelium. Indeed, the wires are quickly coated by endothelial and subintimal tissue which is then remodeled to similate natural blood vessels.
  • an overly exuberant intimal generation can result in pseudointimal hyperplasia which can cause stenosis or obstruction of the shunt.
  • intrahepatic portal-systemic shunts or stents reduce portal venous pressure and blood flow through esophagogastric varices and, by these alterations in the pathophysiology of portal hypertension, reduce the risks of bleeding from varices.
  • surgical portacaval anastomoses have been constructed to accomplish these goals. Although such shunts have been shown to decrease the incidence of bleeding from varices, the surgical risks of such major procedures are considerable.
  • intrahepatic portal-systemic shunting is a much less invasive procedure that is faster, safer and less expensive.
  • liver transplantation in patients with intrahepatic portal-systemic shunts results in a surgery of longer duration, greater difficulty, higher transfusion requirements and perhaps, decreased survival rate.
  • the rigid Palmaz stent has the advantages that it basically cannot migrate in the liver and that it cannot be crushed or flattened by circumferential pressure.
  • the Palmaz stent lacks the flexibility for assuming or negotiating the necessary curved configuration dictated by an intrahepatic portal-systemic shunt. This curved configuration could be negotiated by a series of rigid Palmaz stents connected successfully one to the other in an end-to-end manner, although such a procedure is relatively lengthy and complicated.
  • the WallstentTM flexible stent has the advantage that its intrinsic flexibility allows the stent to easily follow the curved transhepatic tract.
  • the flexibility of the WallstentTM results in that it can be easily flattened or crushed by circumferential pressure and that it can migrate.
  • New endovascular prostheses are proposed for preventing ruptures of esophageal varices and for controlling medico-resistant ascites.
  • an expandable prosthesis for a body passageway comprising first and second substantially tubular members, one of the first and second tubular members being substantially rigid with another one of the first and second tubular members being substantially flexible, the first and second tubular members each having a first collapsed diameter and at least a second expanded diameter, the first and second tubular members being adapted to at least partly overlap one another when installed in the body passageway, whereby the rigid member provides rigidity to the prosthesis while assisting in maintaining in position the prosthesis in the passageway, whereas the flexible member assists the prosthesis in substantially following the orientation of the body passageway.
  • the first and second tubular members are distinct and each define openworks, at least when expanded.
  • the rigid member is adapted to be expanded by outwardly directed radial forces while the flexible member is provided with intrinsic self- expanding forces, the flexible member being longer than the rigid member, whereby when the prosthesis is installed end portions of the flexible member extend outwardly past ends of the rigid member.
  • the rigid member is adapted to be disposed within the flexible member.
  • the flexible member is adapted to be disposed within the rigid member.
  • the expanded diameter of the flexible member is smaller than the expanded diameter of the rigid member, whereby the deployment of the rigid member to the expanded diameter thereof within the flexible member causes at least a central portion thereof located between the end portions thereof to overextend thereby substantially securing the rigid and flexible member one to the other when installed in the body passageway.
  • the rigid member is expanded to an expanded diameter thereof smaller than the expanded diameter of the flexible member thereby restricting the expansion of the flexible member at least at a central portion thereof located between the end portions thereof, whereby end portions of the flexible member expand to a larger diameter than the central portion for substantially securing the rigid and flexible member one to the other when installed in the body passageway.
  • the rigid member is adapted to be expanded by outwardly directed radial forces while the flexible member is provided with intrinsic self-expanding forces, the flexible and rigid members being adapted to be disposed, when installed in the body passageway, in an end-to-end and slightly overlapping relationship.
  • the flexible member comprises a pair of distinct and similar sections with the rigid member being adapted to be disposed between the pair of sections when the prosthesis is installed in the passageway.
  • the rigid member is adapted to be disposed partly within the flexible member, the expanded diameter of the sections of the flexible member being smaller than the expanded diameter of the rigid member, whereby the deployment of the rigid member to the expanded diameter thereof while ends of the rigid member are positioned within the sections of the flexible member causes ends of the sections overlapping the rigid member ends to overextend thereby substantially securing the rigid and flexible member one to the other when installed in the body passageway.
  • a shunting device for a body comprising an expandable prosthesis comprising first and second substantially tubular members, one of the first and second tubular members being substantially rigid with another one of the first and second tubular members being substantially flexible, the first and second tubular members each having a first collapsed diameter and at least a second expanded diameter, catheter means for detachably carrying the prosthesis and for positioning the prosthesis in the body, expansion means for causing the first and second members to extend to the respective expanded diameters thereof, the first and second tubular members being adapted to at least partly overlap one another when installed in the body passageway, whereby the rigid member provides rigidity to the prosthesis while assisting in maintaining in position the prosthesis in the passageway, whereas the flexible member assists the prosthesis in substantially following the orientation of the body passageway.
  • first and second tubular members are distinct and each define openworks, at least when expanded, the rigid member being adapted to be expanded by outwardly directed radial forces while the flexible member is provided with intrinsic self-expanding forces.
  • the flexible member can be longer than the rigid member, whereby when the prosthesis is installed end portions of the flexible member extend outwardly past ends of the rigid member.
  • Figure 1 is a schematic view of an improved shunting device including an intrahepatic portal-systemic stent in accordance with the present invention
  • Figure 2 is an enlarged cross-sectional view taken along lines 2-2 of Figure 1 and showing in detail the intrahepatic portal-systemic stent of the present invention
  • Figures 3 to 8 schematically illustrate, in order, method steps for producing an intrehepatic shunt using the shunting device of Figure 1 and specifically the intrahepatic portal-systemic stent of Figure 2;
  • Figure 9 is a schematic view of a liver incorporating a shunt produced by a further intrahepatic portal-systemic stent in accordance with a second embodiment of the present invention.
  • a method in accordance with the present invention provides for the installation of a rigid, Palmaz-type, stent positioned in a hepatic parenchymal tract previously defined in the liver by way of known methods for connecting the systemic and portal veins. Furthermore, a flexible WallstentTM- type stent is then positioned inside the rigid Palmaz-like stent with the flexible stent being longer than the rigid stent in order that the ends of the flexible stent extend into the systemic and portal veins, whereas a central portion of the flexible stent opposite the rigid stent and the rigid stent itself are positioned in the hepatic parenchyma.
  • the provision of the flexible stent ensures that the fistula so-created follows the curve of the parenchymal tract joining the systemic and portal veins.
  • the rigid stent helps in the prevention of the crushing of the anasmosis and also helps in preventing the unit made of the flexible and rigid stents from migrating in the liver.
  • the flexible stent will be deployed at least partly against the inside of the rigid stent for preventing the migration of the flexible stent.
  • the rigid stent can be deployed within the flexible stent and possibly to a diameter larger than that of the flexible stent thereby "over-extending" the flexible stent substantially opposite the rigid stent and thus securing the flexible stent to the rigid stent and preventing migration of the flexible stent in the liver.
  • an intrahepatic portal- systemic shunting device D which is schematically illustrated in Fig. 1.
  • the present shunting device D embodies both a flexible and a rigid stent as will be explained in details hereinbelow.
  • the rigid stent of the shunting device D is adapted to be deployed by internal pressure using a balloon catheter, whereas the flexible stent is distended by withdrawal of a sheath.
  • a balloon catheter 10 is lowered as seen in Fig. 3 and positioned across the parenchymal tract joining in the liver L the hepatic and portal veins H and P, respectively, as seen in Fig. 4.
  • the balloon catheter 10 is then inflated with contrast medium to a predetermined diameter, e.g. 10 mm, as seen in Fig. 5.
  • the balloon catheter 10 is then removed from the parenchymal tract, and the shunting device D, which is in fact a delivery catheter on which are mounted a flexible and a rigid stent, is then passed in an introducer sheath (not shown) and guided along a guide wire 12 into the parenchymal tract before being deployed thereat for producing the anasmosis. It is noted that the guide wire 12 was left in the liver L when the balloon catheter was removed. Accordingly, the delivery catheter or shunting device D is inserted over the guide wire 12 and is led to the parenchymal tract thereby.
  • the shunting device D which is in fact a delivery catheter on which are mounted a flexible and a rigid stent
  • the shunting device D comprises a pair of coaxial tubes 14 which include inner and outer tubes 16 and 18, respectively.
  • a stainless steel tube 20 is inserted in the proximal end of the outer tube 18 and abuts therein a proximal end of the inner tube 16.
  • the proximal end of the outer tube 18 is secured to a valve body 22 with the stainless steel tube 20 extending through the valve body 22 right up to the proximal end of the inner tube 16.
  • a proximal end of the stainless tube 20 is provided with a hub 24, whereby the guide wire 12 can extend through the stainless steel tube 20 and within the inner tube 18 of the coaxial tubes 14.
  • a stopcock 26 is joined to the valve body 22 by way of an extension delivery tube 28 in such a way that fluid delivered through the stopcock 26, in an open position thereof, will be delivered to the annular passage defined in the coaxial tubes 14 between the inner and outer tubes 16 and 18.
  • the distal end of the stainless tube 20 is sealingly connected to the proximal end of the inner tube 16 in order to prevent fluid conveyed through the stopcock 26 from entering the inner tube 16.
  • the distal end of the guide wire 12 defines an elbow 30 which can act as a stopper, as explained hereinbelow.
  • the distal end of the coaxial tubes 14 is enlarged as embodying the rigid and flexible stents as well as other features which will now be presented.
  • the outer tube 18 at the distal end thereof forms a two-ply invaginated rolling membrane 32 which comprises cylindrical inner and outer sheaths 34 and 36, respectively.
  • a proximal end of the inner sheath 34 is bonded at 38 to the outside of the inner tube 16, with the proximal end of the outer sheath 36 corresponding ' to a continuation of the outer tube 18 upstream of the rolling membrane 32.
  • fluid delivered through the stopcock 26 will be delivered along the annular passage defined between the inner and outer tubes 16 and 18 and, at the beginning or proximal end of the rolling membrane 32, the fluid will flow into the annular passage defined between the inner and outer sheaths 34 and 36 of the rolling membrane 32.
  • a rigid Palmaz-type stent 40 is positioned, in its compressed state, between the inner tube 16 and the inner sheath 34 of the rolling membrane 32.
  • the inner tube 16 is of a more elastic material so that fluid under pressure delivered in a lumen 42 defined in the inner tube 16 (and through which the guide wire 12 extends) will cause the inner tube 16 to inflate within the rigid stent.
  • This inflatable portion of the inner tube 16 is referenced by the numeral 44 in Fig. 2.
  • a flexible WallstentTM-type stent 46 which is longer than the rigid stent 40 is disposed over the flexible stent 46 and between the inner tube 16 and the inner sheath 34 of the rolling member 32.
  • Proximal and distal marker bands 48 are provided around the inner tube 16 adjacent to the proximal and distal ends of the flexible stent 46.
  • the distal end of the inner tube 16 is joined to a distal tip 50 which is of T-shaped cross-section while defining a central aperture for receiving therethrough the guide wire 12.
  • the rolling membrane 32 at the folded distal end thereof surrounds the smaller proximal section of the distal tip 50 while generally abutting the enlarged distal section thereof.
  • a seal may be provided at the central aperture of the distal tip 50 and/or on the guide wire 12, at a location downstream of the distal tip 50, in order to prevent leakage of a fluid supplied in the inner tube 16 through the central aperture of the distal tip 50.
  • the flexible stent 46 can be deployed by removing its covering sheath, that is the rolling membrane 32.
  • a fluid under pressure is supplied in the inner tube 16, possibly by way of the proximal end of the stainless tube 20, that is at the hub 24 thereof, whereby the inflatable portion 44 of the inner tube 16 will inflate thereby causing the controlled deployment of the rigid stent 40.
  • the inflatable portion 44 thus resembles an angioplasty balloon and a saline solution can be used therefor.
  • Figs. 1 and 2 can be installed in the parenchymal tract defined in the liver L between the portal and hepatic veins P and H, respectively, in accordance with the following method and reference is further made to Figs. 6 to 8 on that matter.
  • the valve body 22 can be slidably displaced along the stainless steel tube 20 in direction of the hub 24 thereof while not displacing the stainless steel tube 20 and the hub 24 in order that the inner tube 16 remains set thereby preventing relative displacement of the flexible and rigid stents 46 and 40 with respect to the parenchymal tract.
  • a proper position of the flexible and rigid stents 46 and 40 is obtained by monitoring the position of the radiopaque marker bands 38.
  • the rolling membrane 32 becomes hydraulically pressurized between the inner and outer sheaths 34 and 36 thereof, at which point the rolling membrane 32 can be retracted by displacing the valve body 22 towards the hub 24 in order to deploy the flexible stent 46.
  • the outer tube 18 is connected to the valve body 22, the outer tube 18 is retracted along the stainless steel tube 20 also in direction of the hub 24, whereby the outer tube 10 retracts the outer sheath 36 of the rolling membrane 32 thereby displacing the fold of the rolling membrane 32 from the distal tip 30 in direction of the outer tube 18.
  • the progressive retraction of the rolling membrane 32 uncovers the flexible stent 46 (from its distal end towards its proximal end) and, once the inner and outer sheaths 34 and 36 of the rolling membrane 32 are not superposed and are both disposed around the inner tube 16 upstream of the bonded area 38 of the inner sheath 34 to the inner tube 16, the flexible stent 46 will become completely distended as it is self-expanding.
  • the rolling membrane 32 is shown retracted from the flexible stent 46, whereby the flexible stent 46 is deployed.
  • the rolling membrane 32 and the outer tube 18 have been retracted, whereby the rigid stent 40 can now be distended using hydraulic pressure supplied in the lumen 42 of the inner tube 16.
  • pressure supplied in the lumen 42 will cause the balloon portion 44 to inflate with the rigid stent 40 being distended thereby up to a predetermined diameter.
  • Fig. 7 can also be considered to show both the flexible and rigid stents 46 and 40 in their respective deployed positions.
  • the inner tube 16 and the distal tip 50 attached thereto are then retracted by sliding within the expanded flexible and rigid stents 46 and 40.
  • the guide wire 12 is also removed and Fig. 8 shows the end prostheses in place.
  • the rigid stent 40 is basically positioned in the hepatic parenchyma whereas both flexible end portions of the flexible stent 46, that is the portions thereof located outwards of the rigid stent 40, are basically located in the hepatic and portal veins H and P, respectively. This configuration follows generally the curve required when joining the hepatic and portal veins H and P.
  • blood flowing upwards in the portal vein P towards the liver L will at least partly engage in the anastomosis produced by the flexible and rigid stents 46 and 40 and flow directly into the portal vein P, thereby substantially bypassing the liver L.
  • the rigid stent 40 By distending the rigid stent 40 to a diameter which is greater than that of the flexible stent 46 when the latter is deployed, the rigid stent 40 will exert outward radial pressure on a central portion of the flexible stent 46, thereby preventing the migration of the flexible stent 46 in the liver L.
  • Fig. 9 is similar to Fig. 8 but illustrates a variant of the shunting device D of Figs. 1 and 2 and, more particularly, the flexible stent 46 of Fig. 8 is replaced by a pair of shorter flexible stents 46' which partly overlap the ends of the rigid stent 40.
  • a rigid stent which is overlapped at only one of its ends by a flexible stent, that is basically the configuration shown in Fig. 9 but with only one flexible stent 46'.
  • the rolling membrane 32 is again first retracted for allowing the aforementioned proximal and distal portions of the flexible stent 46 to expand with the central portion of the flexible stent 46 located opposite the rigid stent 40 being prevented from deployment by the still collapsed rigid stent 40. Then, the inflatable portion 44 of the inner tube 16 located opposite the rigid stent 40 is inflated to deploy the rigid stent 40 with the central portion of the flexible stent 46 following due to its inherent self-expanding characteristic the deployment of the rigid stent 40.
  • the inflatable portion 44 of the inner tube 16 located opposite the rigid stent 40 is inflated to deploy the rigid stent 40 with the central portion of the flexible stent 46 following due to its inherent self-expanding characteristic the deployment of the rigid stent 40.
  • the present shunting devices are intended for patients awaiting a hepatic graft.
  • the present shunting devices there is a decrease in the risks of rupture of the esophageal varices, in the risk of medico-resistant ascites while also improving the quality of life of the patients awaiting a graft.
  • the present shunting devices can prolong the lives of patients which can therefore remain eligible for receiving a hepatic graft while impeding the deterioration of the patients' health.
  • an introducer sheath should always be used for implanting the prosthesis as it will protect the hepatic tract especially in case a partially deployed stent must be withdrawn.
  • the introducer sheath must be at a certain distance from the proximal area to be stented for allowing the rolling membrane to be retracted towards the introducer sheath during deployment of the flexible stent without the rolling membrane becoming inserted in the introducer sheath and thus possibly preventing the deployment of the stent.
  • the radiopaque marker bands 48 identify the constrained length of the stent but, since the stent shortens upon deployment, the markers 48 can only be used as approximate markers of the final stent position. Accordingly, radioscopic visualization of the stent itself is necessary to ensure precise stent placement.
  • the shunting device D can be pulled back slightly if partially deployed too far distally in the parenchymal tract, but a flexible stent 46 that is deployed too proximal cannot be advanced.
  • the valve body 22 is gently slid up the stainless steel tube 20 toward the hub 24 while not pushing on the delivery system as the stainless steel tube 20 must be immobilized securely in order to prevent misalignment of the shunting device D and possible vessel damage. If the flexible stent 46 is partially deployed too far distally from the lesion sight, the flexible stent 46 can be pulled back but it is required to first deflate the rolling membrane 32. At least half of the flexible stent 46 must still be constrained by the rolling membrane 32 in order that the shunting device D may be repositioned in the parenchymal tract. After repositioning, the rolling membrane 32 is repressurized.
  • the implanted flexible stent may be further expanded by using a balloon dilatation catheter.
  • the rigid stent With the present shunting device D, the rigid stent
  • dilatation balloon 40 and its dedicated dilatation balloon 44 can be used to further expand the flexible stent 46 at least at the portion thereof located opposite the rigid stent 40.
  • An independent dilatation balloon could be used to over-expand the end portions of the flexible stent 46.
  • routine post-procedure portography can be performed to demonstrate the location and patency of the shunting device D.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Une prothèse dilatable à positionner dans une voie parenchymateuse reliant dans le foie les veines sus-hépatiques et porte, comprend un premier élément tubulaire rigide ainsi qu'un second élément tubulaire flexible. Les premier et second éléments tubulaires présentent chacun un premier diamètre replié ainsi qu'un second diamètre dilaté, ils sont adaptés pour se chevaucher au moins partiellement lorsqu'ils sont installés dans ce passage de l'organisme. Fondamentalement, l'élément rigide confère une rigidité à la prothèse tout en aidant à la maintenir en position dans le passage, tandis que l'élément flexible aide la prothèse à suivre l'orientation du passage de l'organisme. Dans un dispositif de dérivation, un cathéter achemine de manière amovible la prothèse et la positionne dans le corps. On utilise un ballonnet dilatable afin de dilater l'élément tubulaire rigide, tandis que l'élément tubulaire flexible, lequel présente des forces d'auto-dilatation intrinsèques, se dilate lorsque l'on retire la gaine. Par conséquent, les éléments tubulaires rigide et flexible sont dilatés jusqu'à atteindre leurs diamètres dilatés respectifs.
PCT/CA1995/000124 1994-03-04 1995-03-03 Protheses endovasculaires hepatiques WO1995023563A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17521/95A AU1752195A (en) 1994-03-04 1995-03-03 Endovascular hepatic prostheses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20651194A 1994-03-04 1994-03-04
US08/206,511 1994-03-04

Publications (2)

Publication Number Publication Date
WO1995023563A1 true WO1995023563A1 (fr) 1995-09-08
WO1995023563B1 WO1995023563B1 (fr) 1995-09-21

Family

ID=22766723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000124 WO1995023563A1 (fr) 1994-03-04 1995-03-03 Protheses endovasculaires hepatiques

Country Status (2)

Country Link
AU (1) AU1752195A (fr)
WO (1) WO1995023563A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033532A2 (fr) * 1996-03-13 1997-09-18 Medtronic, Inc. Prothese endoluminale et therapies pour des organes du corps humain a plusieurs lumieres et rameaux
EP0800801A1 (fr) * 1996-04-10 1997-10-15 Advanced Cardiovascular Systems, Inc. Stent comportant sur sa longueur une résistance structurale variable
US5824040A (en) * 1995-12-01 1998-10-20 Medtronic, Inc. Endoluminal prostheses and therapies for highly variable body lumens
US6273910B1 (en) 1999-03-11 2001-08-14 Advanced Cardiovascular Systems, Inc. Stent with varying strut geometry
US6468302B2 (en) 1999-04-22 2002-10-22 Advanced Cardiovascular Systems, Inc. Variable strength stent
US6544278B1 (en) 1998-11-06 2003-04-08 Scimed Life Systems, Inc. Rolling membrane stent delivery system
US6576009B2 (en) 1995-12-01 2003-06-10 Medtronic Ave, Inc. Bifurcated intraluminal prostheses construction and methods
US6605110B2 (en) 2001-06-29 2003-08-12 Advanced Cardiovascular Systems, Inc. Stent with enhanced bendability and flexibility
US7763198B2 (en) 2005-04-12 2010-07-27 Abbott Cardiovascular Systems Inc. Method for retaining a vascular stent on a catheter
US7947207B2 (en) 2005-04-12 2011-05-24 Abbott Cardiovascular Systems Inc. Method for retaining a vascular stent on a catheter
US8628565B2 (en) 2005-04-13 2014-01-14 Abbott Cardiovascular Systems Inc. Intravascular stent
US9931232B2 (en) 2010-10-21 2018-04-03 Boston Scientific Scimed, Inc. Stent delivery system
US9943399B2 (en) 2013-01-23 2018-04-17 Cook Medical Technologies Llc Stent with positioning arms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525896A1 (fr) * 1982-04-30 1983-11-04 Wallsten Hans Prothese comprenant un corps tubulaire dilatable ou contractable et son procede d'implantation
EP0421729A2 (fr) * 1989-10-02 1991-04-10 Medtronic, Inc. Dilatateur ensemble
EP0435518A1 (fr) * 1989-12-29 1991-07-03 Med Institute, Inc. Cathéter à l'épreuve de flambage flexible
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
EP0541443A1 (fr) * 1991-11-08 1993-05-12 Meadox Medicals, Inc. Endoprothèse pour implantation transluminale

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525896A1 (fr) * 1982-04-30 1983-11-04 Wallsten Hans Prothese comprenant un corps tubulaire dilatable ou contractable et son procede d'implantation
EP0421729A2 (fr) * 1989-10-02 1991-04-10 Medtronic, Inc. Dilatateur ensemble
EP0435518A1 (fr) * 1989-12-29 1991-07-03 Med Institute, Inc. Cathéter à l'épreuve de flambage flexible
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
EP0541443A1 (fr) * 1991-11-08 1993-05-12 Meadox Medicals, Inc. Endoprothèse pour implantation transluminale

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283991B1 (en) 1995-12-01 2001-09-04 Medtronics Inc. Endoluminal prostheses and therapies for highly variable body lumens
US5824040A (en) * 1995-12-01 1998-10-20 Medtronic, Inc. Endoluminal prostheses and therapies for highly variable body lumens
US6576009B2 (en) 1995-12-01 2003-06-10 Medtronic Ave, Inc. Bifurcated intraluminal prostheses construction and methods
US6843803B2 (en) 1995-12-01 2005-01-18 Medtronic Vascular, Inc. Bifurcated intraluminal prostheses construction and methods
WO1997033532A3 (fr) * 1996-03-13 1997-11-13 Medtronic Inc Prothese endoluminale et therapies pour des organes du corps humain a plusieurs lumieres et rameaux
WO1997033532A2 (fr) * 1996-03-13 1997-09-18 Medtronic, Inc. Prothese endoluminale et therapies pour des organes du corps humain a plusieurs lumieres et rameaux
EP0800801A1 (fr) * 1996-04-10 1997-10-15 Advanced Cardiovascular Systems, Inc. Stent comportant sur sa longueur une résistance structurale variable
US6027526A (en) * 1996-04-10 2000-02-22 Advanced Cardiovascular Systems, Inc. Stent having varied amounts of structural strength along its length
US6942682B2 (en) 1998-11-06 2005-09-13 Boston Scientific Scimed, Inc. Rolling membrane stent delivery system
US8377109B2 (en) 1998-11-06 2013-02-19 Boston Scientific Scimed, Inc. Rolling membrane stent delivery system
US6544278B1 (en) 1998-11-06 2003-04-08 Scimed Life Systems, Inc. Rolling membrane stent delivery system
US7794488B2 (en) 1998-11-06 2010-09-14 Boston Scientific Scimed, Inc. Rolling membrane stent delivery system
US6273910B1 (en) 1999-03-11 2001-08-14 Advanced Cardiovascular Systems, Inc. Stent with varying strut geometry
US6602284B2 (en) 1999-04-22 2003-08-05 Advanced Cardiovascular Systems, Inc. Variable strength stent
US6852124B2 (en) 1999-04-22 2005-02-08 Advanced Cardiovascular Systems, Inc. Variable strength stent
US6468302B2 (en) 1999-04-22 2002-10-22 Advanced Cardiovascular Systems, Inc. Variable strength stent
US6605110B2 (en) 2001-06-29 2003-08-12 Advanced Cardiovascular Systems, Inc. Stent with enhanced bendability and flexibility
US7763198B2 (en) 2005-04-12 2010-07-27 Abbott Cardiovascular Systems Inc. Method for retaining a vascular stent on a catheter
US7947207B2 (en) 2005-04-12 2011-05-24 Abbott Cardiovascular Systems Inc. Method for retaining a vascular stent on a catheter
US8221112B2 (en) 2005-04-12 2012-07-17 Abbott Cardiovascular Systems, Inc. Method for retaining a vascular stent on a catheter
US8628565B2 (en) 2005-04-13 2014-01-14 Abbott Cardiovascular Systems Inc. Intravascular stent
US9931232B2 (en) 2010-10-21 2018-04-03 Boston Scientific Scimed, Inc. Stent delivery system
US9943399B2 (en) 2013-01-23 2018-04-17 Cook Medical Technologies Llc Stent with positioning arms

Also Published As

Publication number Publication date
AU1752195A (en) 1995-09-18

Similar Documents

Publication Publication Date Title
US6491719B1 (en) Tubular endoluminar prosthesis having oblique ends
US7481836B2 (en) Prosthesis with coupling zone and methods
EP1259192B1 (fr) Dispositif endovasculaire avec extenseur
ES2662946T3 (es) Expansión direccional de dispositivos intraluminales
US5810871A (en) Stent delivery system
CA2575306C (fr) Dispositif de mise en place a force de deploiement reduite
US7331985B2 (en) Apparatus and method for deployment of an endoluminal device
US6174316B1 (en) Stent delivery system
JP3773594B2 (ja) ステントと血管移植片の結合アセンブリ
JP4532070B2 (ja) 脈管内人工補綴物
US20070173921A1 (en) Flared stents and apparatus and methods for delivering them
WO2012068298A1 (fr) Dispositifs et procédés de traitement de dissections vasculaires
JPH1119219A (ja) ステント
WO2003071989A1 (fr) Procede et systeme de deploiement de dispositifs endoluminaux a parties multiples
JP2005103321A (ja) 管腔内人工器官の解放配置のための装置
JPH11347133A (ja) 端部キャップ付きの管腔内支持組立体
JPH0852165A (ja) 管腔内移植片配置のための装置及び方法
WO1995023563A1 (fr) Protheses endovasculaires hepatiques
US7815656B2 (en) Method for endovascular bypass stent graft delivery
US9486346B2 (en) Balloon expandable stent graft and apparatus and method for expanding a balloon expandable stent graft
AU776872B2 (en) Bifurcated endoluminal prosthesis
AU780149B2 (en) Non-thrombogenic stent jacket

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA